British Journal of Haematology · 2001 · 125 citations · 13 references
Life SciencesImmunologyPharmacotherapyClinical ImmunologyImmunotherapyTransplant ImmunologyAutoimmune DiseasesGraft-versus-host DiseaseImmune-mediated Inflammatory DiseasesTransplant ImmunopharmacologyTransplant ImmunotherapyTransplant Infectious ComplicationsGraft Versus Host Disease ModulationGraft Versus Host Disease-associated InfectionsGraft-versus-host Disease PathophysiologySteroid-refractory Graft-versus-host Disease
Competitive inhibition of interleukin 2-dependent lymphocytes by daclizumab demonstrates some beneficial effects in the treatment of graft-versus-host disease (GVHD). Sixteen patients with steroid refractory GVHD received daclizumab (1 mg/kg BW) on d 1, 2 (-5), 7, 14 and 21. Twelve patients suffered from grade III-IV acute GVHD and four patients from extensive chronic GVHD. Responses were observed in nine patients (six acute, three chronic GVHD). Fourteen out of 16 patients acquired infections during daclizumab treatment and three deaths were infection related. Daclizumab demonstrates limited activity and is associated with an increased incidence of infectious complications.
13